Pr HARLE Alexandre

Fiche personne

Coordonnées

Unité de biologie des tumeurs
Institut de cancérologie de Lorraine
6 avenue de Bourgogne
54511 VANDOEUVRE-LES-NANCY Cedex

03 83 65 61 19

Territoire

Lorraine

Statut

Hospitalo-Universitaire

Affiliation

Institut de cancérologie de Lorraine (ICL)

Université de Lorraine (UL)

Centre de Recherche en Automatique de Nancy (CRAN) - UMR 7039 (CRAN)

Équipes/plateformes

UMR 7039 - Equipe "Biologie, Signaux et Systèmes en Cancérologie et Neurosciences (BioSIS)"

Service de biologie moléculaire des tumeurs - Département de biopathologie / ICL - CHRU Nancy

Projets

Biopsie liquide pour l'évaluation de l'hétérogénéité clonale et de l'évolution tumorale chez les patientes atteints d'un cancer du sein hormono-dépendant traité par anti-CDK4/6 (CICLADES-CE)

2020 - Porteur du projet : Pr HARLE Alexandre - Partenaire : Pr MERLIN Jean-Louis , Dr MASSARD Vincent

Projet structurant "ADN Tumoral circulant" (Pancréas ctDNA)

2015 - Porteur du projet : Dr PENCREACH Erwan - Partenaire : Dr BOIDOT Romain , Pr HARLE Alexandre , Pr PRETET Jean-Luc

Publications

Genetic variant interpretation in tumours in the French national ring trials Gen&Tiss - main criteria of improvement.

Kalimulaeva M, Van Langenhoven L, Leroy K, Soubeyran I, Harle A, Lamy A, Lacroix L, Fetique D, Gaire A, Bellocq JP, Dequeker E, Rouleau E

Virchows Arch. 2026 02 6;:

Evaluation of the Idylla IDH1-2 Mutation Assay for the Detection of IDH Variants in Solid Tumors and Hematological Malignancies

Gilson P, Muller M, Gauchotte G, Fadil S, Husson M, Hanriot I, Witz A, Dardare J, Betz M, Merlin JL, Harlé A

Int J Mol Sci. 2026 01 20;27(2):

Sensitive cell-free DNA assay for accurate detection of RAS and BRAF mutations in liquid biopsies of patients with metastatic colorectal cancer: Final results of the multicentric ColoBEAM study.

Harlé A, Gavoille C, Bouché O, Abdelghani MB, Plaza J, Spaeth D, Boudrant A, Ghiringhelli F, Villing AL, Borg C, Rouyer M, Husson M, Gilson P, Salleron J, Lambert A, Merlin JL

Oncol Lett. 2026 01;31(1):13

Radiotherapy in the management of PDAC, from past to present.

Dardare J, Martz N, Witz A, Betz M, Michel C, Gilson P, Merlin JL, Lambert A, Harle A

Transl Oncol. 2025 12 8;63:102632

Phase IV international prospective validation of the EORTC patient satisfaction core questionnaire (EORTC PATSAT-C33) and outpatient module (EORTC OUT-PATSAT7).

Brédart A, Kop JL, Shamieh O, Fox L, Alrjoub W, Conroy T, Turhal NS, Arraras IJ, Bultijnck R, Harle A, Van Hemelrijck M, Pinto E, Roth EJU, Ioannidis G, Costantini A, Chalk T, Young T, Rohde G, Ishiki H, Kikawa Y, Schmidt H, Vassiliou V, Shayler S, Marchal F, Amélie A, Lehmann J,

BMC Cancer. 2025 11 26;25(1):1824

Characteristics of WT pancreatic adenocarcinomas: results of a large French multicentric cohort.

Trystram N, Cros J, Blons H, Garinet S, Nicolle R, Le Corre D, Zhao SL, Biagi J, Harlé A, Conroy T, Rebours V, Taïeb J, Dahan L, Laurent-Puig P, Bachet JB

Ther Adv Med Oncol. 2025 11 17;17:17588359251339939

Analytical Validation of a Pan-Cancer NGS Assay for In-House Liquid Biopsy Testing: An International Multicenter Study.

Lescuyer G, Harlé A, Shankar Kumar H, Constantoulakis P, Pfarr N, Heitzer E, Michon C, Russo G, Speel EM, Piecyk M, Husson M, Christopoulou G, Mayr EM, Koppermann ML, Passot C, Graf R, Aoul AH, Bourdon V, Dubbink HJ, van Marion R, Demers I, Dingemans AC, Troncone G, Pepe F, Muinelo-Romay L, Díaz-Lagares Á, Rodriguez-Casanova A, Lago Lestón RM, Pathak D, Shah P, Parillaud RV, Martínez de Ilarduya O, Behr J, Rapin A, Vetterli T, Boppudi SM, Malapelle U, Payen L

J Mol Diagn. 2025 09 25;:

Improving Radiation Therapy in Pancreatic Cancer Through Radiosensitization Strategies.

Dardare J, Martz N, Witz A, Betz M, Michel C, Gilson P, Merlin JL, Lambert A, Harle A

Int J Radiat Oncol Biol Phys. 2025 09 16;:

A novel ddPCR assay for BRCA1 and RAD51C methylation: Advancing HRD Detection in Ovarian Cancer.

Michel C, Simon A, Witz A, Hanriot I, Dardare J, Betz M, Brun M, Gilson P, Merlin JL, Harlé A

J Mol Diagn. 2025 08 7;:

A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function score: The UCGI 41 HESTIA TRIAL DESIGN AND PRELIMINARY SAFETY Data.

Bourien H, Adhoute X, Campillo-Gimenez B, Bouattour M, Assenat E, Nahon P, Launay S, Oberti F, Saviano A, Decaens T, Merle P, Harlé A, Lecomte T, Ternant D, Monard L, Pezzella V, Blanc JF, Edeline J

Dig Liver Dis. 2025 08 1;:

Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics.

Witz A, Dardare J, Betz M, Michel C, Husson M, Gilson P, Merlin JL, Harlé A

Biomark Res. 2025 02 21;13(1):31

Decoding mutational signatures in breast cancer: Insights from a multi-cohort study.

Betz M, Witz A, Dardare J, Michel C, Massard V, Boidot R, Gilson P, Merlin JL, Harlé A

Transl Oncol. 2025 02 4;53:102315

DDB2 expression lights the way for precision radiotherapy response in PDAC cells, with or without olaparib.

Dardare J, Witz A, Betz M, François A, Lamy L, Husson M, Demange J, Rouyer M, Lambert A, Merlin JL, Gilson P, Harlé A

Cell Death Discov. 2024 09 27;10(1):411

REGN5093-M114: can an antibody-drug conjugate overcome the challenge of resistance to epidermal growth factor receptor and mesenchymal epithelial transition tyrosine kinase inhibitors in non-small cell lung cancer?

Dardare J, Witz A, Harlé A

Transl Lung Cancer Res. 2024 08 31;13(8):2082-2086

Impact of Positive Resection Margins on Recurrence and Survival Following Resection and Adjuvant Chemotherapy in Pancreatic Cancer: Results of the PRODIGE 24-CCTG PA-6 Randomized Controlled Trial.

Lambert A, Salleron J, Harlé A, Biagi JJ, Leroux A, Thomas J, Monard L, Cros J, Marchal F, Ayav A, Conroy T

Ann Surg. 2024 07 23;:

Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma.

Fraunhoffer N, Hammel P, Conroy T, Nicolle R, Bachet JB, Harlé A, Rebours V, Turpin A, Abdelghani MB, Mitry E, Biagi J, Chanez B, Bigonnet M, Lopez A, Evesque L, Lecomte T, Assenat E, Bouché O, Renouf D, Lambert A, Monard L, Mauduit M, Cros J, Iovanna J, Dusetti N

Ann Oncol. 2024 06 19;:

Tumor-derived cell-free DNA and circulating tumor cells: partners or rivals in metastasis formation?

Witz A, Dardare J, Betz M, Gilson P, Merlin JL, Harlé A

Clin Exp Med. 2024 01 17;24(1):2

GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles.

Pozzorini C, Andre G, Coletta T, Buisson A, Bieler J, Ferrer L, Kempfer R, Saintigny P, Harlé A, Vacirca D, Barberis M, Gilson P, Roma C, Saitta A, Smith E, Consales Barras F, Ripol L, Fritzsche M, Marques AC, Alkodsi A, Marin R, Normanno N, Grimm C, Müllauer L, Harter P, Pignata S, Gonzalez-Martin A, Denison U, Fujiwara K, Vergote I, Colombo N, Willig A, Pujade-Lauraine E, Just PA, Ray-Coquard I, Xu Z

Cell Rep Med. 2023 12 19;4(12):101344

Integrated Molecular Characterization of HER2-Low Breast Cancer Using Next Generation Sequencing (NGS).

Merlin JL, Husson M, Sahki N, Gilson P, Massard V, Harlé A, Leroux A

Biomedicines. 2023 11 28;11(12):

Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial.

Nicolle R, Bachet JB, Harlé A, Iovanna J, Hammel P, Rebours V, Turpin A, Ben Abdelghani M, Wei A, Mitry E, Lopez A, Biagi J, François E, Artru P, Lambert A, Renouf DJ, Monard L, Mauduit M, Dusetti N, Conroy T, Cros J

J Clin Oncol. 2023 11 14;:JCO2202668

CRISPR/Cas9-mediated knock-in of BRCA1/2 mutations restores response to olaparib in pancreatic cancer cell lines.

Witz A, Dardare J, Francois A, Husson M, Rouyer M, Demange J, Merlin JL, Gilson P, Harlé A

Sci Rep. 2023 10 31;13(1):18741

Gene Mutations and Liquid Biopsy in ER-Positive Breast Cancers: A Small Step Forward, a Giant Leap for Personalization of Endocrine Therapy?

Betz M, Massard V, Gilson P, Witz A, Dardare J, Harlé A, Merlin JL

Cancers (Basel). 2023 10 27;15(21):

Validation of the Idylla GeneFusion assay to detect fusions and MET exon-skipping in non-small cell lung cancers.

Gilson P, Pouget C, Belmonte R, Fadil S, Demange J, Rouyer M, Lacour J, Betz M, Dardare J, Witz A, Merlin JL, Harlé A

Sci Rep. 2023 08 9;13(1):12909

Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol.

Geoffrois L, Harlé A, Sahki N, Sikanja A, Granel-Brocard F, Hervieu A, Mortier L, Jeudy G, Michel C, Nardin C, Huin-Schohn C, Merlin JL

BMC Cancer. 2023 06 16;23(1):554

DDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy.

Dardare J, Witz A, Betz M, Francois A, Meras M, Lamy L, Lambert A, Grandemange S, Husson M, Rouyer M, Demange J, Merlin JL, Harlé A, Gilson P

Front Oncol. 2022 12 8;12:1052163

Development of a Clinical-Biological Model to Assess Tumor Progression in Metastatic Pancreatic Cancer: Post Hoc Analysis of the PRODIGE4/ACCORD11 Trial.

Egea J, Salleron J, Gourgou S, Ayav A, Laurent V, Juzyna B, Harlé A, Conroy T, Lambert A

Cancers (Basel). 2022 10 16;14(20):

Deciphering Tumour Heterogeneity: From Tissue to Liquid Biopsy.

Gilson P, Merlin JL, Harlé A

Cancers (Basel). 2022 Mar 8;14(6):

Intraoperative prediction of non-sentinel lymph node metastases in breast cancer using cytokeratin 19 mRNA copy number: A retrospective analysis.

Pina H, Salleron J, Gilson P, Husson M, Rouyer M, Leroux A, Rauch P, Marchal F, Käppeli M, Merlin JL, Harlé A

Mol Clin Oncol. 2022 Mar;16(3):58

Standardisation of pathogenicity classification for somatic alterations in solid tumours and haematologic malignancies.

Koeppel F, Muller E, Harlé A, Guien C, Sujobert P, Trabelsi Grati O, Kosmider O, Miguet L, Mauvieux L, Cayre A, Salgado D, Preudhomme C, Karayan-Tapon L, Tachon G, Coulet F, Lespagnol A, Beroud C, Leroy K, Rouleau E, Soubeyran I

Eur J Cancer. 2021 Oct 23;159:1-15

Epithelial to Mesenchymal Transition in Patients with Pancreatic Ductal Adenocarcinoma: State-of-the-Art and Therapeutic Opportunities.

Dardare J, Witz A, Merlin JL, Bochnakian A, Toussaint P, Gilson P, Harlé A

Pharmaceuticals (Basel). 2021 Jul 29;14(8):

A NGS-based Blood Test for the Diagnosis of Invasive HPV-associated Carcinomas with Extensive Viral Genomic Characterization.

Sastre-Garau X, Diop M, Martin F, Dolivet G, Marchal F, Charra-Brunaud C, Peiffert D, Leufflen L, Dembele B, Demange J, Tosti P, Thomas J, Leroux A, Merlin JL, Diop-Ndiaye H, Costa JM, Salleron J, Harle A

Clin Cancer Res. 2021 Jun 9;:

Evaluation of the Idylla ctEGFR mutation assay to detect EGFR mutations in plasma from patients with non-small cell lung cancers.

Gilson P, Saurel C, Salleron J, Husson M, Demange J, Merlin JL, Harlé A

Sci Rep. 2021 May 18;11(1):10470

Detection of Microsatellite Instability: State of the Art and Future Applications in Circulating Tumour DNA (ctDNA).

Gilson P, Merlin JL, Harlé A

Cancers (Basel). 2021 Mar 24;13(7):

Evaluation of 3 molecular-based assays for microsatellite instability detection in formalin-fixed tissues of patients with endometrial and colorectal cancers.

Gilson P, Levy J, Rouyer M, Demange J, Husson M, Bonnet C, Salleron J, Leroux A, Merlin JL, Harlé A

. 2020 Oct 2;10(1):16386

Comparison of pathogenicity prediction tools on somatic variants.

Suybeng V, Koeppel F, Harlé A, Rouleau E

J Mol Diagn. 2020 Oct 1;:

SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal Adenocarcinoma.

Dardare J, Witz A, Merlin JL, Gilson P, Harlé A

Int J Mol Sci. 2020 May 16;21(10):

Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue.

Litchfield K, Stanislaw S, Spain L, Gallegos LL, Rowan A, Schnidrig D, Rosenbaum H, Harle A, Au L, Hill SM, Tippu Z, Thomas J, Thompson L, Xu H, Horswell S, Barhoumi A, Jones C, Leith KF, Burgess DL, Watkins TBK, Lim E, Birkbak NJ, Lamy P, Nordentoft I, Dyrskjøt L, Pickering L, Hazell S, Jamal-Hanjani M, ,Larkin J, Swanton C, Alexander NR, Turajlic S

Cell Rep. 2020 May 5;31(5):107550

Cell-Free DNA in the Management of Colorectal Cancer.

Harlé A

Recent Results Cancer Res.. 2020 ;215:253-261

Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer.

Franczak C, Witz A, Geoffroy K, Demange J, Rouyer M, Husson M, Massard V, Gavoille C, Lambert A, Gilson P, Gambier N, Scala-Bertola J, Merlin JL, Harlé A

PLoS ONE. 2020 ;15(1):e0227294

Identification of Specific Tumor Markers in Vulvar Carcinoma Through Extensive Human Papillomavirus DNA Characterization Using Next Generation Sequencing Method.

Thomas J, Leufflen L, Chesnais V, Diry S, Demange J, Depardieu C, Bani MA, Marchal F, Charra-Brunaud C, Merlin JL, Leroux A, Sastre-Garau X, Harlé A

J Low Genit Tract Dis. 2020 Jan;24(1):53-60

Pathology of HPV-Associated Head and Neck Carcinomas: Recent Data and Perspectives for the Development of Specific Tumor Markers.

Sastre-Garau X, Harlé A

Front Oncol. 2020 ;10:528957

Emerging Roles of DDB2 in Cancer.

Gilson P, Drouot G, Witz A, Merlin JL, Becuwe P, Harlé A

Int J Mol Sci. 2019 Oct 18;20(20):

Somatic substitution signature as an innovative tool in lung cancer diagnosis.

Busca S, Salleron J, Boidot R, Merlin JL, Harlé A

Sci Rep. 2019 Oct 10;9(1):14561

Dual Epigenetic Regulation of ERα36 Expression in Breast Cancer Cells.

Thiebaut C, Chesnel A, Merlin JL, Chesnel M, Leroux A, Harlé A, Dumond H

Int J Mol Sci. 2019 May 29;20(11):

Uncommon mutational profiles of metastatic colorectal cancer detected during routine genotyping using next generation sequencing.

Franczak C, Kandathil SM, Gilson P, Husson M, Rouyer M, Demange J, Leroux A, Merlin JL, Harlé A

Sci Rep. 2019 May 8;9(1):7083

HPV insertional pattern as a personalized tumor marker for the optimized tumor diagnosis and follow-up of patients with HPV-associated carcinomas: a case report.

Harlé A, Guillet J, Thomas J, Demange J, Dolivet G, Peiffert D, Leroux A, Sastre-Garau X

BMC Cancer. 2019 Mar 28;19(1):277

Technical considerations for circulating tumor DNA detection in oncology.

Franczak C, Filhine-Tresarrieu P, Gilson P, Merlin JL, Au L, Harlé A

Expert Rev. Mol. Diagn.. 2019 Jan 16;:

Evaluation of KRAS, NRAS and BRAF hotspot mutations detection for patients with metastatic colorectal cancer using direct DNA pipetting in a fully-automated platform and Next-Generation Sequencing for laboratory workflow optimisation.

Gilson P, Franczak C, Dubouis L, Husson M, Rouyer M, Demange J, Perceau M, Leroux A, Merlin JL, Harlé A

PLoS ONE. 2019 ;14(7):e0219204

Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma.

Franczak C, Dubouis L, Gilson P, Husson M, Rouyer M, Demange J, Leroux A, Merlin JL, Harlé A

PLoS ONE. 2019 ;14(2):e0212801

Comparison of Three Real-Time PCR Assays for the Detection of PIK3CA Somatic Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Breast Carcinomas.

Lambert A, Salleron J, Lion M, Rouyer M, Lozano N, Leroux A, Merlin JL, Harlé A

Pathol. Oncol. Res.. 2018 Nov 13;:

Clinical Interests of Circulating Tumor DNA in Oncology.

Franczak C, Filhine-Tressarieu P, Broséus J, Gilson P, Merlin JL, Harlé A

Arch. Med. Res.. 2018 Nov 7;:

Nuclear factor I X is a recurrent target for HPV16 insertions in anal carcinomas.

Jeannot E, Harlé A, Holmes A, Sastre-Garau X

Genes Chromosomes Cancer. 2018 Sep 27;:

Detection of ALK, RET, ROS1, NTRK1 and MET rearrangements and actionable mutations using next generation sequencing in patients with non-small cell lung cancer.

Harlé A, Dietmaier W, Vogl I, Neumann K, Haumaier F, Beggs AD, Pestinger V, Grand D, Tallet A, Merlin JL

Ann. Oncol.. 2018 Sep;29 Suppl 6:vi12

Absence of correlation between radiation-induced CD8 T-lymphocyte apoptosis and sequelae in patients with prostate cancer accidentally overexposed to radiation.

Vogin G, Merlin JL, Rousseau A, Peiffert D, Harlé A, Husson M, Hajj LE, Levitchi M, Simon T, Simon JM

Oncotarget. 2018 Aug 24;9(66):32680-32689

Accelerated mutation analysis using a fully automated PCR platform improves the management of patients with metastatic melanoma.

Serre D, Salleron J, Husson M, Leroux A, Gilson P, Merlin JL, Geoffrois L, Harlé A

Oncotarget. 2018 Aug 14;9(63):32232-32237

Evaluation and validation of HPV real-time PCR assay for the detection of HPV DNA in oral cytobrush and FFPE samples.

Harlé A, Guillet J, Thomas J, Sastre-Garau X, Rouyer M, Ramacci C, Gilson P, Dubois C, Dolivet G, Leroux A, Salleron J, Merlin JL

Sci Rep. 2018 Jul 27;8(1):11313

[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].

Loriot MA, Ciccolini J, Thomas F, Barin-Le-Guellec C, Royer B, Milano G, Picard N, Becquemont L, Verstuyft C, Narjoz C, Schmitt A, Bobin-Dubigeon C, Harle A, Paci A, Poinsignon V, Quaranta S, Evrard A, Hennart B, Broly F, Fonrose X, Lafay-Chebassier C, Wozny AS, Masskouri F, Boyer JC, Etienne-Grimaldi MC

Bull Cancer. 2018 Apr;105(4):397-407